Back8-K ↗8-K ↗
BPMC
Blueprint Medicines Corp
Blueprint Medicines is a commercial-stage biopharmaceutical company developing small molecule kinase inhibitors for oncology and rare diseases, with AYVAKIT (avapritinib), marketed as AYVAKYT in Europe, approved and being commercialized for gastrointestinal stromal tumor. The company is advancing additional drug candidates through clinical development and faces risks including competition, regulatory approval uncertainties, clinical trial enrollment challenges, and the need to achieve profitability from its marketed and pipeline programs.
$129.46+14.10%1Y
BPMC · daily close · illustrative · 0 catalysts marked
Pipeline
UnknownIndication pending review
Catalyst Calendar
JAN–JAN
ReadoutBLU-808
“$2.00 per CVR, payable upon the dosing of the fifth patient in the first Phase 2b Study or the first Phase 3 Study (whichever occurs first) for BLU-808, the Company's potent and selective wild-type KIT inhibitor (the "Product"), in any indication. The applicable milestone period will expire on December 31, 2028.”
JAN–JAN
NDABLU-808
“$4.00 per CVR, payable upon receipt from the U.S. Food and Drug Administration (the "FDA") by Aventis or its affiliates (including the Company continuing as the surviving corporation) of approval by the FDA of the new drug application for the Product, that is necessary for the commercial marketing and sale of the Product in the United States for any indication. The applicable milestone period will expire on June 30, 2032.”